Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 1
Part ~ Assessment Program Profiles anc! Report Citations

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Part I: Assessment Program Profiles arid Report Citations This part has two major sections. Beginning on page 3 are profiles of 68 medical technology assessment programs, with citations of their approximately 3,200 complet- ed, ongoing, and planned assessments. The assessment program profiles are listed alphabetically by name of parent organization. Following the profiles, beginning on page 254, is a subject index to report citations, to be used for locating citations on particular subjects among the profiles. The index has approximately 1,900 subject terms. These terms are listed alphabetically, each followed by one or more relevant assessment report codes. Each code has a two letter prefix . .. . indicating an assessment program and a number indicating the report's placement in the list of citations at the end of the program's profile earlier in Part 1. A list of prefixes and their respective programs is shown on page 252, immediately preceding the subject index.

OCR for page 1
AMERICAN ACADEMY OF NEUROLOGY American Academy of Neurology Practice Committee 2221 University Overdue SE, Suite 335 Minneapolis, MN 55414 612-623-81 15 Contact: Richard P. Hames, Director, Division of Medical Services and Communica- tions; William H. Stuart M.D., 105 Collier Rd. NW, Suite 1030, Atlanta, GA 30309, 404-351-2270; or John P. Conomy M.D., Department of Neurology, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44106, 216-444-5555. Overview: The American Academy of Neurology (AAN) is a 9,000-member medical specialty society founded in 1948. The Academy's major objectives are to stimulate the growth and development of the specialty of clinical neurology and clinical neurologists. The AAN Practice Committee assesses the clinical effectiveness of drugs, devices, and procedures involving the neurosciences. Purpose: To review and evaluate clinical, procedural, and technological requests for opinion received by the Academy. Primary iIItended users: Providers, generally; physicians; health/medical professional associations; third party payers; government regulators. Technologies: Medical or.surmr~71 brnr~l.q~.r~ it Fir vw, 5vvwv c, ~v~ww~ ~ MA ~ ~ V A~- Intervention: Treatment, diagnosis, rehabilitation. Stage: New, established or widespread practice, obsolete. Properties: Effectiveness; safety; efficacy; cost; service requirements; acceptance/adop- tion level; ethical, legal, social implications. Selection process: Individual practitioners in neurology and neurosurgery, medical organizations, and third party payers can request that an assessment be conducted. All requests must be in writing and sent to the Academy office. Requests are submitted to the Practice Committee for opinion and inclusion on the agenda. The Practice Commit- tee does not set assessment topic priorities. The Committee, acting as a group, assesses all questions submitted to it, although the Committee has rejected such complicated topics as organ transplantation. 3

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Methods: Group judgment, expert opinion. The Practice Committee receives reports from several subcommittees that are, in most cases, chaired by a Practice Committee member. The subcommittees consider the procedure/treatment question and exercise one of two options: 1) develop recommen- dation for full committee as to whether the treatment/procedure is established, investi- gational, unacceptable, or indeterminate (as defined in accordance with the American Medical Association (AMA) Diagnostic and Therapeutic Technology Assessment plan); or 2) defer recommendation pending further research/study by subcommittee members. At each of the four regularly scheduled meetings per year the Practice Committee reviews and acts on the recommendations of the subcommittees. Practice Committee actions are then submitted to the Academy Executive Board as information items. The following statement is incorporated into every response to a request for opinion: "This response is provided as a service of the American Academy of Neurology. It is based on current scientific and clinical information through (date of evaluation), and does not represent endorsement by the AAN of particular diagnostic and therapeutic procedures or treatment." When major questions or issues confront the Committee, such as the use of magnetic resonance imaging as a diagnostic procedure, a wider consensus is sought. Working with the Council of Medical Specialty Societies (CMSS), the AMA, and other organiza- tions, a consensus panel is convened and a position paper developed on the technology . . . In question. The turnaround time from selection of assessment topic to reporting of findings ranges from 1 week to 6 months. Assessors: The Practice Committee is composed of 16 members from across the country who represent the interests and concerns of the practitioner. Assessment reports include: Who sponsored/commissioned/ supported the assess- ment; stage of life-cycle of technology when assessed; recommendations for practice, future assessments, technology development, research. Dissemination: Assessment results are disseminated through the minutes of the Prac- tice Committee and through correspondence with other medical organizations and practitioners. The Academy office maintains a listing of Practice Committee decisions and responds to inquiries about procedures/treatment. The Council of Medical Spe- cialty Societies also distributes Practice Committee assessments. Budget: The assessment program is not budgeted as a separate activity. The approxi- mate cost per assessment is not known. Use: The Academy disseminates assessment results to its membership. Based on inquires received, third party payers rely on Practice Committee opinions in making reimbursement decisions. 4

OCR for page 1
AMERICAN ACADEMY OF NEUROLOGY Completed Reports AA1 American Academy of Neurology, Practice Com- mittee. Extracranial-intracranial bypass surgery for treatment or prevention of stroke. 1986 Feb. tExpert opinion, Group judgment] AA2 . Hyperbaric oxygen therapy for treatment of senility, multiple sclerosis, and cerebral edema. 1986 Feb. tExpert opinion, Group judgment] AA3 . Apheresis (therapeutic) in the treatment of Guillain-Barre Syndrome.1985 fun. LExpert opin- ion, Group judgment] AA4 . Apheresis in treatment of systemic lupus erythematosus. 1985 fun. tExpert opinion, Group judgment] AA5 . Percutaneous transluminal angioplasty (PTA). 1985 Feb. tExpert opinion, Group judgment] AA6 . Topographic mapping. 1985. Feb. LEx- pert opinion, Group judgment] AA7 . Apheresis in treatment of chronic relaps- ing polyneuropathy. 1984 Feb. LExpert opinion, Group judgment] AA8 . Autopsies on patients with slow virus dis- eases. 1984 Nov. [Expert opinion, Group judgments AA9 . EEG guidelines for epileptic mentally re- tarded.1984 Nov. [Expert opinion, Groupjudgment] AA10 . Electromyographic biofeedback in treat- ment of hyperactivity. 1984 Feb. [Expert opinion, Group judgment] AA11 . Electronystagmography. 1984 Jun. LEx- pert opinion, Group judgment] AA12 . Functional integration in the alleviation of chronic muscular pain and spasticity. 1984 Feb. LExpert opinion, Group judgment] AA13 . Nuclear magnetic resonance. 1984 Feb. fExpert opinion, Group judgment] AA14 . Sterotactic cingulatomy. 1984 Nov. LEx- pert opinion, Group judgment] AA15 . Amyotrophic lateral sclerosis injected modified neurotoxin for treatment. 1983 Feb. fEx- pert opinion, Group judgment] AA16 . Edinburgh Masker for stuttering. 1983 Jun. tExpert opinion, Group judgment] AA17 . Histamine desensitization for cluster headache. 1983 Jun. [Expert opinion, Group judg- ment] AA18 . Melodic intonation therapy for aphasia. tExpert opinion, Group judgment] AAl9 . Modified neurotoxin in the treatment of ALS. 1983 fun. fExpert opinion, Group judgment] AA20 . Plasmapheresis in treatment of multiple sclerosis. 1983 Feb. fExpert opinion, Group judg- ment] AA21 . Plasmapheresis in treatment of myasthe- nia gravis. 1983 Feb. fExpert opinion, Group judg- ment] AA22 . Somatosensory evoked response. 1983 Nov. tExpert opinion, Group judgment] AA23 . Trancutaneous electrical nerve stimula- tion for treatment of acute pain for ambulatory pa- tients. 1983 Nov. fExpert opinion, Group judgment] AA24 . Twenty-four hour EEG ambulatory monitoring. 1983 Jun. tExpert opinion, Group judg- ment] AA25 . Biofeedback for headaches. 1982 Jun. [Expert opinion, Group judgment] AA26 . Carotid infusion of BCNU for glioblas- toma multiforme. 1982 Jun. tExpert opinion, Group judgment] AA27 . Cerebellar stimulator implantation for cerebral palsy. 1982 Oct. tExpert opinion, Group judgment] AA28 . Cerebellar stimulator implantation.1982 Jun. LExpert opinion, Group judgment] AA29 . Cochleostomy with neurovascular trans- plant in treatment of Meniere's Disease. 1982 Oc- t.tExpert opinion, Group judgment] AA30 . EEG monitoring-ambulatory. 1982 Apr. fExpert opinion, Group judgment] AA31 . EEG monitoring during open-heart sur- gery and immediate post-operative period. 1982 Oct. LExpert opinion, Group judgment] AA32 . Negative pressure respirators for home use in chronic neuromuscular disease. 1982 Oct. LEx- pert opinion, Group judgment] AA33 . Spinal cord stimulation for treatment of cerebral palsy. 1982 Jun. tExpert opinion, Group judgment] AA34 . Taste and smell clinics. 1982 Jun. fEx- pert opinion, Group judgment] AA35 . Acupuncture.1981 Jul. [Expert opinion, Group judgment] AA36 . Apheresis for multiple sclerosis. 1981 ~ul. FExpert opinion, Group judgment] 5

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY AA37 . EEG interpretation and brain stem evoked response. 1981 Jul. fExpert opinion, Group judgment] AA38 . Electrical nerve stimulation of post-sur- gical pain. 1981 Apr. fExpert opinion, Group judg- ment] AA39 . Electrical stimulation for treatment of Bell's Palsy. 1981 Apr. tExpert opinion, Group judg- ment] AA40 . Electrical stimulation for treatment of facial nerve palsy.1981 May. [Expert opinion, Group judgment] AA41 . Histamine therapy for Men~tre's Dis- ease. 1981 Jul. LExpert opinion, Group judgment] AA42 . Prolotherapy.1981 Jul. Expert opinion, Group judgment] AA43 . Visual evoked potentials. 1981 Jul. tEx- pert opinion, Group judgment] American Academy of Ophthalmology Ophthalmic Procedures Assessment Program PO Box 7424 655 Beach Street San Francisco, CA 94120-7424 415-561-8500 AA44 . Biofeedback treatment for migraine headache. 1980 Apr. LExpert opinion, Group judg- ment] AA45 . Continuous EEG monitoring during surgery. 1980 Apr. tExpert opinion, Group judg- ment1 AA46 . Intracranial pressure monitors. 1980 Oct. FExpert opinion, Group judgment] AA47 . Neurosonology. 1980 Mar. FExpert opinion, Group judgment] AA48 . Spinal stimulation for multiple sclerosis. 1980 May. tExpert opinion, Group judgment] AA49 . Transfer factor treatment in multiple sclerosis. 1980 Apr. fExpert opinion, Group judg- ment] AA50 . Ultrasonic arteriography. 1980 May. fExpert opinion, Group judgment] Contact: Lea Gamble, Director Health Policy Research; or David L. Guyton, M.D., Chairman, Committee on Ophthalmic Procedures Assessment, Wilmer Ophthalmo- logical Institute, the Johns Hopkins Hospital, Baltimore, MD 21205, 301-955-8314. Overview: The American Academy of Ophthalmology (AAO) is a professional associa- tion composed of over 14,000 physicians trained in the specialty of ophthalmology. It offers a wide range of membership services including continuing education programs, public and professional information materials, and scientific meetings. The Ophthal- mic Procedures Assessment Program is the medical technology assessment program of the AAO. Purpose: To present state-of-the-science information about ophthalmic technologies that will help Academy members make informed decisions about patient care. Primary intended users: Physicians, third party payers, government regulators. Technologies: Medical or surgical procedure, drug, device. Ophthalmology-related orphan drugs and products, diagnostic and therapeutic de- vices, and medical and surgical procedures are assessed. Intervention: Treatment, diagnosis. 6

OCR for page 1
AMERICAN ACADEMY OF OPHTHALMOLOGY Stage: Nell', emerging, established or widespread practice. Sufficient information must be available in the scientific literature to develop assess- ments. Properties: Safety, effectiveness, efficacy. Comprehensive assessments usually follow this format: definition of terms, including development of technique or procedure, extent of current use; clinical implementa- tion, including indications for use, comparison to conventional methods, advantages/ disadvantages, patient population most likely to benefit, and effectiveness; safety; qualifications necessary to use technique; and current research and summary. Selection process: Academy members, public and private third party payers, and government agencies can request that assessments be conducted. Requests will also be accepted from other sources. Usually requests for assessments are written inquiries asking the Academy's position/opinion on a certain technology. Inquiries from individ- uals and private third party payers are frequently received over the telephone, but the AAO requires that a written request be submitted. The Committee on Ophthalmic Procedures Assessment sets priorities. Technologies to be assessed must be within the scope of ophthalmology, and sufficient scientific information on which to base a decision must be available. If new information is available that substantially changes . ~ . . . .. Information contained In an assessment, a reassessment of the technology will be . . . 1nltlatec A. Methods: Information syntheses, group judgment, expert opinion, epidemiological and other observational methods. The scientific literature in refereedjournals is reviewed and expert opinion and group judgment is sought in order to reach consensus. After a decision to evaluate a technol- ogy has been made, the following four steps are followed: 1) an expert is identified who develops a draft with references; 2) the draft is reviewed by other experts, generally AAO members, the Committee, staff, and legal counsel; 3) if substantial changes are needed, a revised draft is recirculated to all reviewers and, generally, a conference call is held to discuss differences in interpretation of findings in the literature; and 4) once a draft is acceptable to the reviewers, it is submitted to the Academy's Board of Directors for approval. For noncontroversial technologies, the average turnaround time from selection of assessment topic to reporting of findings is 6 to 9 months. For controversial technol- ogies the turnaround time can extend into years. Assessors: The Committee is composed of three Academy members, staffed by the Academy's Office of Health Policy Research, and assisted by the membership of the Academy. Academy members participate as reviewers, as in-depth consultants, or by preparing the original draft assessment. A total of 400 Academy members, covering 40 technical areas, have agreed to participate, in some capacity, in the assessment effort. These members participate voluntarily and without remuneration. When appropriate, experts from related fields are consulted. 7

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Assessment reports include: Who conducted the assessment; description of the tech- nology; properties assessed; sources of data/information; findings or conclusions; recommendations for practice, future assessments, technology development, research; how the technology works, including theory, principles; development of the technol- ogy. Dissemination: Printed reports; journal articles; press conferences/news releases, TV/ radio broadcasts, video products. The Academy prints the assessment reports, and notices of completed assessments appear in the AAO membership newsletter. The assessments are published in the AAO's scientific journal, displayed at the AAO annual meeting, and are mailed to specific organizations and interested individuals. l he Academy's Order Department accepts telephone and written requests for assessment reports. Copies are provided free of charge. Budget: $7,500. Funding source: 100 percept sponsors/members dues, contributions. Use: Assessment reports are considered an educational service to the members and are provided in response to inquiries from the media, third party payers, and the public. Private and public third party payers use them to make policy decisions about coverage. Their purpose for requesting an assessment is generally stated. Related activities: At the 1986 AAO annual meeting, the Committee on Ophthalmic Procedures Assessment sponsored a special scientific session entitled, "Radial Kerato- tomy in Perspective." The purpose of this session was to have opthalmolog~sts repre- senting a range of opinions address key questions about the procedure. Completed Reports AB1 American Academy of Ophthalmology. Epikerato- phakia procedures for the correction of severe hyper- opia, myopia, and keratoconus. San Francisco, CA: American Academy of Ophthalmology, expected completion October 1987. "Information syntheses, Expert opinion] AB2 . Punctal occlusion for the dry eye. San Francisco, CA: American Academy of Ophthalmolo- gy, 1987. [Information syntheses, Expert opinions AB3 . Punctoplasty for siccakeratitis. San Fran- cisco, CA: American Academy of Ophthalmology, ex- pected completion June 1987. "Information synthe- ses, Expert opinions AB4 . Radial keratotomy for myopia. San Fran- cisco, CA: American Academy of Ophthalmology, ex- pected completion October, 1987. "Information syn- theses, Expert opinion] AB5 . Cataract surgery in the 1980's. San Fran- cisco, CA: American Academy of Ophthalmology, 1987. "Information syntheses, Expert opinion] 8 AB6 . Keratophakia and keratomileusis: safety and effectiveness. San Francisco, CA: American Academy of Ophthalmology, 1986. [Information syn- theses, Expert opinions AB7 . Thymoxamine: the need for orphan drug status. San Francisco, CA: American Academy of Ophthalmology, 1986. [Information syntheses, Ex . . pert opinions AB8 . Botulinum toxin therapy of eye muscle disorders: safety and effectiveness. San Francisco, CA: American Academy of Ophthalmology, 1984. [Information syntheses, Expert opinion] AB9 Committee on Ophthalmic Procedures Assess- ment. "American Academy of Ophthalmology] Car- bon dioxide laser surgery in head and neck surgery. San Francisco, CA: American Academy of Ophthal- mology, 1984. "Information syntheses, Expert opin- ion] AB10 . "American Academy of Ophthalmology] Cyanoacrylate tissue adhesive. San Francisco, CA: American Academy of Ophthalmology, 1984. tInfor- mation syntheses, Expert opinion]

OCR for page 1
AMERICAN ACADEMY OF OPHTHALMOLOGY AB11 . American Academy of Ophthalmology] Therapeutic contact lenses for recurrent corneal ero- sion. San Francisco, CA: American Academy of Oph- thalmology, 1984. Information syntheses, Expert . . Opmlon AB 12 Keltner ~L. fAmerican Academy of Ophthalmol- ogy] Academy recommendation: automated peri- metry. Ophthalmology 1984;91:51-56. [Information syntheses, Expert opinion] American Academy of Pediatrics 141 Northwest Point Boulevard PO Box 927 Elk Grove Village, IL 60009-0927 3 12-228-5005 Contact: lean Lockhart, M.D. AB13 Trokel S. "American Academy of Ophthalmolo- gy] Academy recommendation: ophthalmic neodym- ium YAG lasers: safety and effectiveness. Ophthal- mology 1984;91:539-42. Information syntheses, Ex . . pert opinion AB14 American Academy of Ophthalmology. Laser trabecular surgery for open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmolo- gy, 1983. fInformation syntheses, Expert opinion] Overview: The American Academy of Pediatrics (AAP) is a professional association composed of pediatricians and pediatric medical and surgical subspecialists. The Acad- emy promotes optimal physical, mental, and social health for infants, children, adoles- cents, and young adults. It provides a range of services including advocacy for children and pediatrics, health systems delivery research, public information and education, continuing medical education, and analyses and review of child health policy issues. The Academy's technology assessment activities are an integral part of the information gathering and advisory functions of the numerous AAP Committees. Purpose: The AAP Committees keep abreast of developments in the field and advise the membership and Executive Board on topics within the committees' areas of exper- tise. Primary intended users: General public; physicians; health/medical professional asso- ciations; government regulators; public policy-makers, legislators; policy research or- ganizations; liability, malpractice insurers. Technologies: Drug, device, medical or surgical procedure, support system, organiza . ~ . . . tuna or administrative system. Intervention: Prevention, diagnosis, treatment, rehabilitation. Stage: Emerging, new, established or widespread practice. Properties: Safety; efficacy; effectiveness; service requirements; system impact; ethical, legal, social implications. Selection process: Topic suggestions can come from any source. Usually, assessment topics are suggested by committee members, AAP members, or through other organi- zational requests. The AAP accepts telephone and written requests and occasionally relies on formal contracts. For example, the Food and Drug Administration contracted 9

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY with the AAP for advice relative to infant formulas and drugs. AAP staff screen the requests and then the appropriate committee considers the question. Assessment topic priorities are set by the individual committee and the Academy. Methods: Information syntheses, expert opinion, group judgment. The assessment method varies from committee to committee and by issue, although all committees generally rely on a type of group judgment. For statements, committees usually proceed in the following manner: 1) general discussion of issue; 2) preparation of first draft by committee member; 3) extensive review and preparation of bibliogra- phy by same member (in some cases, this information is reviewed by outside consul- tants); 4) presentation of second draft and discussion by committee; and, 5) revision of draft, if necessary. All reports must be approved by the Executive Board of the AAP. The average turnaround time from selection of assessment topic to reporting of findings ranges from 4 months to 1 year. Assessors: AAP has committees in such areas as adolescence, bioethics, drugs, fetus and newborn, hospital care, infectious diseases, nutrition, radiology, and surgery. Each committee consists of experts in the topic area. Committees can also bring in consul- tants for additional expertise on particular reports. Dissemination: Printed reports; advisories to members/constituents; press confer- ences/news releases, TV/radio broadcasts. Committees issue reports with the assessment findings. For smaller scale projects a note is made in the minutes or a recommendation given to the AAP Executive Board. AAP Committee statements are published in Ped~atrics or information may appear in AAP News. Occasionally, letters are sent to government agencies such as the Environmental Protection Agency or the Consumer Product Safety Commission. Some reports are distributed directly to the AAP members, such as the Report of the Committee on Infectious Diseases (the "Red Book". Budget: Not provided. Related activities: The AAP publishes a quarterly newsletter, Child Health Financing Report, which contains the latest information about child health financing for privately insured children and those covered by Medicare. The Academy also sponsors an annual meeting, educational programs, and continuing education courses. Completed Reports AC1 American Academy of Pediatrics, Committee on Hospital Care. Emergency services. Pediatrics (To be published). AC2 , Committee on Hospital Care. Guidelines for air and ground transportation. Pediatrics (To be published). AC3 , Committee on Hospital Care. Quality as- surance of hospital care of children. Pediatrics (To be published). 10 AC4 , Committee on Practice and Ambulatory Medicine. Screening for vision problems. Pediatrics (To be published). AC5 , Committee on Accident and Poison Pre- vention. Revised first aid for the choking child. Pedi- atrics 1986 Jun. AC6 , Committee on Child Health Financing. Medicaid policy statement. Pediatrics 1986 May. AC7 , Committee on Disabilities. Screening for developmental disabilities. Pediatrics 1986 Sep.

OCR for page 1
AMERICAN ACADEMY OF PEDIATRICS AC8 , Committee on Disabilities. Transition of severely disabled children from hospital or chronic care facilities to the community. Pediatrics 1986 Sep. AC9 , Committee on Early Childhood, Adop- tion, and Dependent Care. Oral and dental aspects of child abuse and neglect. Pediatrics 1986 Sep. ACID , Committee on Nutrition. Prudent life- style for children: dietary fat and cholesterol. Pediat- rics 1986 Sep. AC11 , Committee on Practice and Ambulatory Medicine. Vision screening and eye examination in children. Pediatrics 1986 fun. AC12 , Committee on Research. Guidelines for the Pediatric Cancer Center and the role of such cen- ters in diagnosis and treatment. Pediatrics 1986 Jun. ACID , Committee on School Health. CPR train- ing in the school. AAP News 1986 Jan. AC14 , Committee on School Health. School attendance of children and adolescents with human T Iymphotropic virus III/lymphadenopathy-associated virus infection. Pediatrics 1986 Mar. ACID , Committee on School Health. School health examinations. AAP News 1986 Feb. ACID , Committee on Infectious Diseases. Pre- vention of hepatitis B virus infections. Pediatrics 1985 Feb. AC17 , Committee on Bioethics. Proposed guidelines on genetic engineering. Pediatrics 1985 Jun. AC18 , Committee on Disabilities. Assisting disa- bled children. Pediatrics 1985 Jun. ACl9 , Committee on Disabilities. Provision of related services for children with chronic disabilities. Pediatrics 1985 Apr. AC20 , Committee on Drugs. "Inactive" ingredi- ents in pharmaceutical products. Pediatrics 1985 Oct. AC21 , Committee on Drugs. Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 1985 Oct. AC22 , Committee on Drugs. Guidelines for the elective use or conscious use of sedation, deep seda- tion, and general anesthesia in pediatric patients. Pe- diatrics 1985 Aug. AC23 , Committee on Environmental Hazards. Smokeless tobacco-a carcinogenic hazard to chil- dren. Pediatrics 1985. AC24 , Committee on Fetus and Newborn. High risk newborn care. Pediatrics 1985 Jul. ACES , Committee on Fetus and Newborn. Home phototherapy. Pediatrics 1985 Soul. AC26 , Committee on Fetus and Newborn. Vita- min E and the prevention of retinopathy of prematu- rity. Pediatrics 1985 Aug. AC27 , Committee on Hospital Care. Child life programs for hospitalized children. Pediatrics 1985 Sep. AC28 , Committee on Hospital Care. Guidelines for pediatric intensive care units. Pediatrics 1983 Sep. AC29 , Committee on Infectious Diseases. lIe- mophilus type b polysaccharide vaccine. Pediatrics 1985 Aug. AC30 , Committee on Infectious Diseases. Rec- ommendations for using pneumococcal vaccine in children. Pediatrics 1985 Jun. AC31 , Committee on Infectious Diseases. Rec- ommendations for using pneumococcal vaccine in children. Pediatrics 1985 fun. AC32 , Committee on Nutrition. Nutritional needs of low-birth-weight infants. Pediatrics 1985 May. AC33 , Committee on Nutrition. Use of oral fluid therapy and posttreatment feeding following enteritis in children in a developed country. Pediatrics 1985 Feb. AC34 , Committee on Practice and Ambulatory Medicine. Computers in your practice. Pediatrics 1985 Jul. AC35 , Committee on Practice and Ambulatory Medicine. High risk newborn care. Pediatrics 1985 Jul. AC36 , Committee on School Health. Health education and schools. Pediatrics 1985 Jun. AC37 , Committee on Screening Genetics. Ma- ternal phenylketonuria. Pediatrics 1985 Aug. AC38 , Committee on Adolescence. A policy reference guide to the AAP's Council Committee and Executive Board statements. 1984. AC39 , Committee on Drugs. Ethanol in liquid preparations intended for children. 1984. AC40 , Committee on Drugs. Antimicrobial pro- phylaxis in pediatric surgical patients. Pediatrics 1984 Sep. AC41 , Committee on Infectious Diseases. Anti- microbial prophylaxis in pediatric surgical patients. Pediatrics 1984 Sep. 11

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Radiopaque plastics AJ42 Radiopharmaceuticals MR41 Radiotherapy NDlSO Radiowaves FA125 Ranitidine FD25, FD26 Rape AC51 Reading ND27 Reagent kits, Diagnostic SC7 Recall AO22, ND28 Receptors, Dopamine ND63 Receptors, Endogenous substances ND14 Receptors, Steroid NL51 Rectal mucosal replacement CA77 Referral and consultation HF87, NA130 Regent kits, Diagnostic AG46 Reg~onal Renal Failure Program (Canada) HW18 Registries MG27 3OO Regression analysis NA91, NA95 Rehabilitation HFS5, HW1, ND4, ND31, ND36, ND176 Rehabilitation centers HF165 Rehabilitation programs Spinal cord injury HW2 Rehabilitation programs-Stroke HW3 Rehfuss test NC96 Keimbursement UB99 Reimbursement, Incentive HF66, HF111, HF112, UP19 Reimbursement mechan~sms HF33, HF96, HF196 . Relaxation therapy ND86, UB112 Reminder systems MG26, ND119 Renal artery AG58, NC93 Research AC44, NA3, NA4, NA113 Research design FA52, FA183, HF17, H~ F56, LU14, LU21, MG4, NA3, NA11, NH12, NH39, NH57, NH69, NH83, NH106, NH123, NH126, NH137, NM5, NM1 7, NM22 Research support UB77 Reserpine NH88, VC16

OCR for page 1
INDEX TO REPORT CITATIONS Residential mobility NH130 Residential treatment HF16, HF118, HF172, HF181 Respiratory distress syndrome ET8, NH13, NH41, NH111 Respiratory hypersensitivity CA53, CA108 Respiratory system NA79 Respiratory therapy CU63, HF100, MR19 Respiratory therapy department, Hospital HW25 Respiratory tract diseases CA83 Respiratory tract infections ND1 77 Respite care HF1 79 Resuscitation AC13, NA17, NA96 Resuscitation Mouth-to-mouth CA35 Resuscitators FA194 Retinopathy of prematurity AC26 Reuse of disposables FA184, GU1, GU2, GU3, GU6, GU7, GU8, HW9, NC8 Reye's syndrome AC72, NL35 Rh isoimmunization AF4, AF14, ND191 Rheumatology tests UB6 Rhinoplasty CA40 Ringer's irrigation FD1 69 Risk AC76, AM2, FA248, HN80, NA58, NA102, UFO, VC23 Rubella AF29, FA52 Rubella vaccine ND49 Rubidium MR11 Running AC76 Saccharin AO21, CU89 Safety LE1 Salicylates ND164 . . . Salplngltls ND5 Saralasin FD1 70 Satellite communication AN6, NM15, NM16 Scales, Patient EH26 Schizophrenia AG81, MRl l, ND63, ND127 School health services AC45, AC47 3

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Schools AC13, AC14, AC15, AC36, AC46, AC48, AO3 CA12 Scintiphotography Heart NH43 Scintiphotography Joint NC113 Sclerotherapy AG42, AS12, CA57, UB113, VC40 Scoliosis AP26, FA69, FA120, FA123, ND38, ND193 ND194, UB56 S. creenlng AH4, AP22, CA12, ND179 Secretin FD1 71 S. elzures AP28 Selenium sulfide FD49 Self administration ND81 Self care ~F184 Semen preservation ND78 Senility AA2, AG50, NC88 Sensory aids ND46 Seromucoid assay NC98 Severity of illness index HF59, HF60, HF61, HF142, HF186, HF187, NA67, NA108, NA116 302 Sex disorders AF38 Sex hormones CA37 Sexually transmitted diseases AF36, AO49, HN15, ND79 Shape sensor ND37 Shock, Hemorrhagic AF16 Shock, Septic AF15 Shoe insoles ND186 Shoulder dislocation CA1 Siccakeratitis AB3 Sigmoidoscopy AS16 Silver sulfadiazine FD107 Singer-Blom valve operation CA105 . . . Slsomlan FD1 72 Sleep disorders CA92 Slow virus diseases AA8 Smell AA34

OCR for page 1
INDEX TO REPORT CITATIONS Smoke detectors AO6 Smoking AF32, AO30, AO47, NH98, NH116, PA6 Snoring CA76 Social adjustment ND43, ND101, ND125, ND172, ND198 Social behavior ND146 Social support HF65, ND89, ND101 Social work HF136 Socioeconomic factors MM12, ND32 Socket prosthesis ND30, ND35 Sodium AC81 Sodium cellulose phosphate FD27 Sodium chloride FA8, FD70, FD97, FD120, FD121, FD123, FD124 Sodium phosphate FD97 Soft tissue neoplasms NL21 Somatoform disorders UB78 Sorbitol AL10 South Carolina HF189 SPECT imaging ET21 Speech disorders CU43 Speech pathology BS36, NC134 Sperm penetration assay API 7, BS35 Sphincterotomy AG36, AS11 Spinal cord FA140 ~ . . . . ~plna1 corcl 1nJurles VC26 Spinal puncture AG21 Spinal stenosis UB79 Spine CA93, MR45, ND157 Spondylitis, Ankylosing ND66 Sporicidin AK14 Sports AC66, AJ13 Sprinklers AO6 Standardized Medreview Instrument HF1 7, HF26 Stapedectomy CA78 Staphylococcal infections VC20 303

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Stereotaxic depth electrode implantation NC109 Stereotaxic neurosurgery, Computed tomogra phy-assisted ET30 Stereotaxic technics AA14, AP18, CA33, NC26 Stereotyping MM10, MM11 Sterilizers AK6, AN28, EH40 Steroids AE2, VC9 Stomach AS14 Stool guaiac HA38 Streptococcal infections BC14, ND102 Streptococcus pyogenesis ND102 Streptokinase CA71, ET43, JH4, NC50, NH20, UB80 Streptozocin FD109 Stress (Psychology) HN69 Stuttering AA16 Subclavian artery AG55 Substance abuse AC52, AO32, AO54 Substance dependence HW10 304 Sucralfate FD110 Suction equipment EH18, EHl9, EH36 Suction lipectomy CA34 Sudden infant death syndrome AP19, BS33 Suicide DC14, HN16, HN70 Sulfadoxine FD111 Sulfamethoxazole FD176, VC52 Sulfinpyrazone MM17 Suloctidil MM5 Sunlamps FA121 Surgery AC40, AC41, HA33, HA34, HF87, HF159, HF175, HF204, HN63, NA9, NA14, NA45, NA99, ND29, ND117, NH85, PA4, SP8 Surgery-Ambulatory HW14, JH7, UP7 Surgery Arthritis UB8 Surgery Breast CU73 Surgery-Eye UB41 Surgery Fetal AO43, HN45 Surgery-Heart HN24, HN32, NC60

OCR for page 1
INDEX TO REPORT CITATIONS Surgery Impotence NC155 Surgery-Morbid obesity AP24, DC25, ET57, NL61 Surgery Prostate VC33 Surgery Scoliosis MR45, UB56 Surgery department, Hospital CU26 Surgical aids Ophthalmic FA27, FA28, FA2 69, FA271 Surgical case carts EH47, EH48 Surgical drapes EH10 Surgical gloves EH37 Surgical shunt VC6 Surgical stapling CA1 Survival NA116 Sutures FA45, FA99, FA111, FA305 Swan Ganz heart catheter UB83 Syphilis tests BC13 ~ . ~yrlnge pumps NS1 Systeme International units AO20, AO75 Systems analysis NA61 Systolic Hypertension in the Elderly Program NH4, NH21, NH76, NH81 T. ~ amoxlien DC1 1 Tars NDl9O Taste disorders AA34 Tay-Sachs disease AF43 Team care MG23 Technetium 99M oxidronate FD1 77 Technetium Tc 99m aggregated albumin FD50 Technetium Tc 99m disofenin FD1 13 Technetium Tc 99m medronate FD178 Technetium Tc 99m pryprophophates NH43 Technetium Tc 99m pertechnetate NC113 Technetium Tc 99m succimer FD1 12 Technology CU59 Technology assessment, Biomedical ANl 9, AN30, AN31, AO35, AO70, CU58, CU87, CU91, HA5, LE2, LU13, MG22, NA29, NA35, NA63, NA78, SP7, SP12, VH1 3o5

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Technology, Medical CU12, CU35, CU55, CU60, CU81, CU83, CU84, GU4, GUll, GU13, HA26, HA29, HC3, HC5, HN49, LU15, NA44, PH4, SC1, UF7 Telecommunications CU57 Telemetry UP10 Temazepam FD1 79 Temperature NA79 Temporomandibular joint AK1 1 Temporomandibular joint procedure CA55 Tendon transfer ND106 Teratogens AE2 Terminal care HF193 Test interpretation ET11 Tetratogens AC59 Texas HF200 Thalassemia MG5 Thallium AG5 Thallium imaging UB84 Theophylline FD114, MG14 306 Therapeutic drug monitoring ET58 Therapeutic embolization ET59 Therapeutic equivalency CU92 Therapy, Computer-assisted FA182, HF184, NL53 Thermography AH6, AP38, CA93, NC152 Thermography-Breast ET45, NC73 Thermometers EH39, FA189 T. . nlamlne AO51 Tho race n tes is AGl 9, AG28 Thoracic neoplasms AG16 Throat cultures BC14 Thrombocytopenia ND115 Thromboembolism MM5 Thrombolysis in Myocardial Infarction Trial NH20, NH37, NH154 Thrombolytic therapy AG33, CA79, NL43 Thrombophlebitis CB8, ET55, MM13, MM14, MM15, PA3, PA4 Thrombosis NL43

OCR for page 1
INDEX TO REPORT CITATIONS Thrombosis, Venous NL11 Thymoxamine AB7 Thyroid neoplasms CB14 Thyroxine assays UA23 T·1 ' ola ND88 Timolol FD1 15 Tinnitus maskers NC118 Tioconazole FD51 Tissue banks MR4 T. . . . ssue plasmlnogen act~vators DC16, ET54, JH4, NH154 T. . ssue preservation MR18, ND114 Tobacco smoke pollution CU17 Tobacco, Smokeless AC23 Tobramycin FD116 Tocodynamometry BS3, CA5, CU7 Tomography, Standard AG16 Tongue neoplasms DC23 Tonometry DC26 Tonsillectomy CA23, NL57 Tooth extraction NL50 Toothpaste AK2, AK7, AK12, AK13, MG1 Topographic brain mapping AA6, AN3, CA4 Tourniquets EH27 TOXLINE NM20 Trace elements ND45 Tranquilizing agents, Major MR9 Transcutaneous electrical nerve stimulation AA23, CA94, NC51, NC119 Transfer factor AA49 Transillumination Breast AP22, NC52, NC153, ND3 Transplantation AG61, AO10, AO25, CU41, HN2, HN71, MG17, UB67 Transplantation-Bone marrow AP20, CU75, ET29, HN39, MT2, UB14, UB92 Transplantation Bone marrow, Allogenic BS7,HNl9,NC14 Transplantation-Bone marrow, Autologous AP3, BS8, NC16, NC151 Transplantation-Cornea UB39 307

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Transplantation-Heart CA100, HF194, MT13, PH9 Transplantation Heart-lung CA47 Transplantation Kidney HF39, HF176, HN5, MG4, MG6, MG7, MGl l, MG15, NC32 Transplantation Liver AO8, CA73, HN52, MT15, NC69, NC124, NL28 Transplantation Nail bed UB63 Transplantation Pancreas AG54, NC53 Transsexual surgery NC120 Transsexualism HN30 Trazodone FD117 Tr~amterene FD28 Triazolam FD52 Trimethoprim FD118, FD176, FD180, VC3, VC52 T. . rloctanoln AG44 Triolein AG44 Trophoblastic tumor AF30 Tropical medicine CU28 Tryptophan MR10 308 Tubal ligation CA15 Tuberculosis NC77 Tuberculosis screening CA56 Tumor markers ET46 Tumor stem cell assay AG71, CA86, NC114 Type A score NH36 Ulcer AS4, AS7, AS10 Ultrasonography AH5 Ultrasonography-Arteries AA50, AG79, AG80, NC100 Ultrasonography-Follicular growth AE3 Ultrasonography-Head BC31, MR26 Ultrasonography Pancreas HA24 Ultrasonography Pregnancy NK4, NL19 Ultrasonography-Prostate ET72 Ultrasonography Sinuses CA20 Ultrasound AA47, HN3, HN73 Ultrasound Cardiac output NC47

OCR for page 1
INDEX TO REPORT CITATIONS Ultrasound Intraoperative AP10 Ultrasound-Obstetrics and gynecology AF27 Ultrasound-Obstetrics and gynecology Pelvi metry BC35 Ultrasound equipment-Diagnostic HW8 Ultrasound equipment-Therapeutic FA46, NS14 Ultraviolet rays AO19, NC121 Ultraviolet therapy NC122 Unbundling JH8, UB87 Unstable Angina Pectoris Trial NH146, NH150, NH153 Ureteroscopy NC27, NC154 Urinalysis BC15, ET25 Urinary calculi LU3, VC26 Urinary catheterization ND54 Urinary incontinence AF44, CU29, EH33, HF93, SP3 Urinary sphincter, Artificial ET1 Urinary tract infections AF40, ND54, ND128 Urination disorders CA29, ND181 Urine AG82, BC15, NC123 Urography AC92, UB89 Urologic disease screening AC1 09 Urticaria ND164 Uterine hemorrhage AF24 Utilization review HF119 Vaccination policy CU80, CU85, HN58 Vaccines CA95, HN35, SC2 Valproate AC59, AC70, VC45 Vascular access ports ET37, FA302 Vasculitis NC97 Vasodilators VC27, VC28, VC59 Vegetarianism AC1 08 Venous insufficiency AG48, NC38 Ventilation-perfusion lung scans MM8 Ventilators ANl l, EH6, EH49, ET85, FA195 Ventricular assist devices MT14 309

OCR for page 1
MEDICAL TECHNOLOGY ASSESSMENT DIRECTORY Ventricular fibrillation NA62 Verapamil FD29, FD30, FD119, FD181 Vertebral artery AG55 Vertebral artery surgery CA11 Veterans Administration CUl l, CU22, VC13, VH3 Vidarabine FD53 Video recording NM13 Viral antibodies FA52 Viral hepatitis vaccine AG40, AO59, LU4, NH149 Vision SP8 Vision screening AC4, AC11 Vitamin B 12 ND1 73 Vitamin E AC26, MR43, ND108 Vitamins AC87, AO24 Vulvar neoplasms AF12 Warfarin MM13, VC11 Warts CA26 310 Water, Sterile FD1 75 West Virginia UP13 Wheelchairs CU40, HA10, ND95, ND107 Wolff-Parkinson-White syndrome API Women AE17,AF17,AF37,AF44,AO44,AO69,BC15 Work AF31 Wounds and injuries AC65, CBl 9, NA57, NA67 Xenon FD54 Xylitol AL10 Xylose AG45 Yohimbine MR23 Znc ND98 Zomepirac sodium FD182